After-Hours Movers 12/10: (ASNA) Higher; (SEAC) (SFIX) (CAMP) Lower (more...)

December 10, 2018 5:27 PM

After-Hours Movers

SeaChange International, Inc. (NASDAQ: SEAC) 17.4% LOWER; reported third quarter fiscal 2019 revenue of $18.6 million and a U.S. GAAP loss from operations of $2.5 million, or $0.07 per basic share, compared to third quarter fiscal 2018 revenue of $23.4 million and U.S. GAAP income from operations of $0.9 million, or $0.03 per fully diluted share.

Stitch Fix (NASDAQ: SFIX) 13.6% LOWER; reported Q1 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $366.2 million versus the consensus estimate of $357.97 million. Stitch Fix (NASDAQ: SFIX) sees Q2 revenue of $360-$368 million and adjusted EBITDA of $8-$12 million vs consensus revenue of $362 million. Stitch Fix (NASDAQ: SFIX) sees FY revenue of $1.49-$1.53 billion and adjusted EBITDA of $20-$40 million vs consensus revenue of $1.51 billion.

Calamp Corp. (NASDAQ: CAMP) 11.7% LOWER; Updated Q3 Guidance Misses Views

Ascena Retail Group (NASDAQ: ASNA) 11.7% HIGHER; reported Q1 EPS of $0.06, versus $0.00 reported last year. Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.56 billion. Ascena Retail Group sees Q2 2019 EPS of ($0.25)-($0.15), versus the consensus of ($0.12). Ascena Retail Group sees Q2 2019 revenue of $1.675-1.705 billion, versus the consensus of $1.7 billion.

Casey's General Stores (NASDAQ: CASY) 7.6% LOWER; reported Q2 EPS of $1.80, $0.19 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.54 billion.

Quanex (NYSE: NX) 6.8% LOWER; reported Q4 EPS of $0.22, $0.21 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $244.1 million versus the consensus estimate of $246.16 million.

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) 3.2% LOWER; Announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock.

HCP, Inc. (NYSE: HCP) 2.7% LOWER; commenced a public offering of an aggregate of 14,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 12,000,000 shares offered on a forward basis in connection with the forward sale agreement described below. The forward purchaser (as described below) expects to grant the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of the Company's common stock.

Categories

Special Reports

Next Articles